Vaccines
-
340B, Caught my eye, Drug Prices, Generics, Medicare Part D, Medicare Transaction Facilitator, Orphan Drugs, Reference Pricing, VaccinesAMP is WAC — 09/04/25
Read more: AMP is WAC — 09/04/25A Monday off is always a double win, longer weekend and shorter week. Caught My Eye Made me Laugh. 340B can be funny. Go PhRMA. Zebras, Not Unicorns. The Food and Drug Administration announced a new rare disease approval framework. While it acknowledges the challenge of rare disease, it is unclear if the new framework…
-
Inflation Reduction Act, Medicare Advantage, Medicare Part D, Reference Pricing, State-based Reform, Supply Chain, VaccinesAMP is WAC — 8/15/25
Read more: AMP is WAC — 8/15/25Caught my Eye Surely a Coincidence. President Trump called for direct to consumer purchasing at Most Favored Nation Pricing and BlinkRx said that they could offer this service. Donald Trump Jr. is on their board. Lobby Me This. Stat News had an article about a new coalition, IRA Watch, that is formed to discuss…
-
AMP is WAC — 06/20/25
Read more: AMP is WAC — 06/20/25All the summer Friday vibes today, including a cocktail in mind for later. I’ve been trying to top the Paper Plane and the Broken Plane is close. Any other recs, let me know. In the meantime, to-do list in hand and ready to hit the ground running. Caught my Eye Hit Us with Your Best…
-
AMP is WAC — 6/13/25
Read more: AMP is WAC — 6/13/25Caught my Eye Make Believe. This week we were wondering if the Administration would put out information on what the Most Favored Nation (MFN) would be for drugs; that is what is the best price for each drug in a set of country’s that have a GDP at least 60% of ours. But there have…
-
340B, Caught my eye, COVID, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, VaccinesAMP is WAC — 05/30/25
Read more: AMP is WAC — 05/30/25I do love a Monday off. It somehow feels like an a double-treat – you get the Monday off and the week flies by. Yes we had to cram more meetings and work into the shorter week but totally worth it. Caught my Eye Processed Over. This week the Secretary of Health and Human Services,…
-
Caught my eye — 2/28/25
Read more: Caught my eye — 2/28/25Tariffic. This week Eli Lilly announced they were investing at least $27 billion in US manufacturing, which is pretty cool. Was it to buy favor with the new Administration? It certainly does not hurt. I get the allure of manufacturing in the United States. If a country wanted to hurt us, they could stop sending…
-
Caught my eye — 2/21/25
Read more: Caught my eye — 2/21/25Discontinued: A flu vaccination campaign got pulled by the Department of Health and Human Services (HHS). It is off the air and the website was taken offline and now directs users to older information and not the new campaign (“Wild to Mild”.) 1 in 5. Did you know that 1 in 5 people in the…
-
Caught my eye — 2/23/24
Read more: Caught my eye — 2/23/24Gross to Net, a Saga. As soon as I saw Adam Fein’s Drug Channels article on Gross to Net in Part D redesign, I knew it would throw off my day. It was just catchy enough to cause a buzz and get the attention of Heads of Market Access at pharmaceutical companies and start the…
-
Caught my eye — 10/13/23
Read more: Caught my eye — 10/13/23Medicare Math. Medicare Part B premiums will go up about 6% next year, Social Security cost of living adjustment will be 3.2%. Really Stupid Vaccine Policies. Sometimes a story hits just right like this Washington Post opinion piece on RSV vaccines for adults and how the access is harmed by coverage policies. This year two…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)